CO-78 | REAL-WORLD MANAGEMENT OF ACQUIRED HEMOPHILIA A: FOCUS ON RECOMBINANT PORCINE FVIII AS FIRST-LINE HEMOSTATIC TREATMENT AND LONG-TERM OUTCOMES
Background. Acquired Hemophilia A (AHFA) is a rare bleeding disorder caused by the development of neutralizing autoantibodies against endogenous coagulation factor VIII (FVIII). The clinical presentation is often characterized by sudden, severe subcutaneous and mucosal hemorrhages. Management is inherently complex: it...